Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

iBio (IBIO) Other Accumulated Expenses (2020 - 2024)

Historic Other Accumulated Expenses for iBio (IBIO) over the last 7 years, with Q2 2024 value amounting to $460000.0.

  • iBio's Other Accumulated Expenses fell 7630.09% to $460000.0 in Q2 2024 from the same period last year, while for Jun 2024 it was $460000.0, marking a year-over-year decrease of 7630.09%. This contributed to the annual value of $460000.0 for FY2024, which is 7630.09% down from last year.
  • As of Q2 2024, iBio's Other Accumulated Expenses stood at $460000.0, which was down 7630.09% from $1.9 million recorded in Q2 2023.
  • Over the past 5 years, iBio's Other Accumulated Expenses peaked at $1.9 million during Q2 2023, and registered a low of $136000.0 during Q2 2021.
  • Its 5-year average for Other Accumulated Expenses is $586600.0, with a median of $229000.0 in 2022.
  • In the last 5 years, iBio's Other Accumulated Expenses skyrocketed by 74759.83% in 2023 and then plummeted by 7630.09% in 2024.
  • iBio's Other Accumulated Expenses (Quarter) stood at $167000.0 in 2020, then fell by 18.56% to $136000.0 in 2021, then soared by 68.38% to $229000.0 in 2022, then soared by 747.6% to $1.9 million in 2023, then tumbled by 76.3% to $460000.0 in 2024.
  • Its Other Accumulated Expenses stands at $460000.0 for Q2 2024, versus $1.9 million for Q2 2023 and $229000.0 for Q2 2022.